Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline

Clinical Genetics

Volumn 90, Issue 2, 2016, Pages 105-117

  van Os, N J H ^a   Roeleveld, N ^b,c   Weemaes, C M R ^c   Jongmans, M C J ^d   Janssens, G O ^e   Taylor, A M R ^f   Hoogerbrugge, N ^d   Willemsen, M A A P ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e the Netherlands The Innovative Therapies for Children with Cancer Consortium   (Netherlands)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

ataxia telangiectasia; ATM protein; heterozygote; risk factor

Indexed keywords

ATM PROTEIN;

BREAST CANCER; CANCER RISK; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; GENE MUTATION; GENETIC ANALYSIS; HAPLOTYPE; HEALTH HAZARD; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 84978800336     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12710     Document Type: Review

References (68)

1. Savitsky K, Bar-Shira A, Gilad S et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995: 268: 1749–1753.
2. Boder E, Sedgwick RP. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics 1958: 21: 526–554.
3. Sedgwick RP, Boder E. Ataxia-telangiectasia. In: De Jong J, ed. Handbook of clinical neurology hereditary neuropathies and spinocerebellar atrophies, Vol. 16. Amsterdam: Elsevier, 1991: 347–423.
4. Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab 1999: 68: 419–423.
5. Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987: 316: 1289–1294.
6. Janin N, Andrieu N, Ossian K et al. Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer 1999: 80: 1042–1045.
7. Thompson D, Duedal S, Kirner J et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005: 97: 813–822.
8. AT Society UK: AT Carriers. Retrieved from http://www.atsociety.org.uk/a-t-carriers.
9. Castan M. A-T children's project: cancer and the risk of X-ray exposure in A-T carriers 2008, Retrieved from http://www.atcp.org/page.aspx?pid=3423
10. Anheim M, Tranchant C, Koenig M. The autosomal recessive cerebellar ataxias. N Engl J Med 2012: 366: 636–646.
11. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991: 325: 1831–1836.
12. Wells GA SB, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses 2009, from http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
13. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. John Wiley & Sons, Ltd., 2011, from www.cochrane-handbook.org.
14. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008: 336: 924–926.
15. Su Y, Swift M. Mortality rates among carriers of ataxia-telangiectasia mutant alleles. Ann Intern Med 2000: 133: 770–778.
16. Morrell D, Chase CL, Kupper LL, Swift M. Diabetes mellitus in ataxia-telangiectasia, Fanconi anemia, xeroderma pigmentosum, common variable immune deficiency, and severe combined immune deficiency families. Diabetes 1986: 35: 143–147.
17. Olsen JH, Hahnemann JM, Borresen-Dale AL et al. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. Br J Cancer 2005: 93: 260–265.
18. Geoffroy-Perez B, Janin N, Ossian K et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer 2001: 93: 288–293.
19. Swift M, Lukin JL. Breast cancer incidence and the effect of cigarette smoking in heterozygous carriers of mutations in the ataxia-telangiectasia gene. Cancer Epidemiol Biomarkers Prev 2008: 17: 3188–3192.
20. Swift M, Sholman L, Perry M, Chase CL. Malignant neoplasms in the families of patients with ataxia-telangiectasia. Cancer Res 1976: 36: 209–215.
21. Swift M, Chase C. Cancer and cardiac deaths in obligatory ataxia-telangiectasia heterozygotes. Lancet 1983: 1: 1049–1050.
22. Heim RA, Lench NJ, Swift M. Heterozygous manifestations in four autosomal recessive human cancer-prone syndromes: ataxia telangiectasia, xeroderma pigmentosum, Fanconi anemia, and Bloom syndrome. Mutat Res 1992: 284: 25–36.
23. Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996: 92: 130–134.
24. Swift M, Chase CL, Morrell D. Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 1990: 46: 21–27.
25. Geoffroy-Perez B, Janin N, Ossian K et al. Variation in breast cancer risk of heterozygotes for ataxia-telangiectasia according to environmental factors. Int J Cancer 2002: 99: 619–623.
26. Stankovic T, Kidd AM, Sutcliffe A et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 1998: 62: 334–345.
27. Bernstein JL, Teraoka S, Southey MC et al. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271 T > G and c.1066-6 T > G (IVS10-6 T > G) from the Breast Cancer Family Registry. Hum Mutat 2006: 27: 1122–1128.
28. IKNL (Comprehensive Cancer Centre the Netherlands), Knowledge Institute of Medical Specialists (KiMS) and National Breast cancer Organization the Netherlands (NABON); Breast cancer: Dutch Guideline, version 2.0. 2012, from http://www.oncoline.nl/breastcancer
29. Chenevix-Trench G, Spurdle AB, Gatei M et al. Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002: 94: 205–215.
30. Bernstein JL, Bernstein L, Thompson WD et al. ATM variants 7271 T > G and IVS10-6 T > G among women with unilateral and bilateral breast cancer. Br J Cancer 2003: 89: 1513–1516.
31. Tavtigian SV, Oefner PJ, Babikyan D et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009: 85: 427–446.
32. Renwick A, Thompson D, Seal S et al. ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006: 38: 873–875.
33. Baynes C, Healey CS, Pooley KA et al. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 2007: 9: R27.
34. FitzGerald MG, Bean JM, Hegde SR et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 1997: 15: 307–310.
35. Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res 1998: 58: 1376–1379.
36. Bebb DG, Yu Z, Chen J et al. Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer. Br J Cancer 1999: 80: 1979–1981.
37. Becker-Catania SG, Chen G, Hwang MJ et al. Ataxia-telangiectasia: phenotype/genotype studies of ATM protein expression, mutations, and radiosensitivity. Mol Genet Metab 2000: 70: 122–133.
38. Shigeta T, Takagi M, Delia D et al. Defective control of apoptosis and mitotic spindle checkpoint in heterozygous carriers of ATM mutations. Cancer Res 1999: 59: 2602–2607.
39. Delia D, Mizutani S, Panigone S et al. ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and at heterozygotes. Br J Cancer 2000: 82: 1938–1945.
40. Chen PC, Lavin MF, Kidson C, Moss D. Identification of ataxia telangiectasia heterozygotes, a cancer prone population. Nature 1978: 274: 484–486.
41. Paterson MC, Anderson AK, Smith BP, Smith PJ. Enhanced radiosensitivity of cultured fibroblasts from ataxia telangiectasia heterozygotes manifested by defective colony-forming ability and reduced DNA repair replication after hypoxic gamma-irradiation. Cancer Res 1979: 39: 3725–3734.
42. Ramsay J, Birrell G, Lavin M. Breast cancer and radiotherapy in ataxia-telangiectasia heterozygote. Lancet 1996: 347: 1627.
43. Barlow C, Eckhaus MA, Schaffer AA, Wynshaw-Boris A. Atm haploinsufficiency results in increased sensitivity to sublethal doses of ionizing radiation in mice. Nat Genet 1999: 21: 359–360.
44. Worgul BV, Smilenov L, Brenner DJ, Junk A, Zhou W, Hall EJ. Atm heterozygous mice are more sensitive to radiation-induced cataracts than are their wild-type counterparts. Proc Natl Acad Sci U S A 2002: 99: 9836–9839.
45. Weissberg JB, Huang DD, Swift M. Radiosensitivity of normal tissues in ataxia-telangiectasia heterozygotes. Int J Radiat Oncol Biol Phys 1998: 42: 1133–1136.
46. Bremer M, Klopper K, Yamini P, Bendix-Waltes R, Dork T, Karstens JH. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother Oncol 2003: 69: 155–160.
47. Su Y, Swift M. Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations. JAMA 2001: 286: 2233–2234.
48. Mauget-Faysse M, Vuillaume M, Quaranta M et al. Idiopathic and radiation-induced ocular telangiectasia: the involvement of the ATM gene. Invest Ophthalmol Vis Sci 2003: 44: 3257–3262.
49. Barbazetto IA, Room M, Yannuzzi NA et al. ATM gene variants in patients with idiopathic perifoveal telangiectasia. Invest Ophthalmol Vis Sci 2008: 49: 3806–3811.
50. Tanteles GA, Murray RJ, Mills J et al. Variation in telangiectasia predisposing genes is associated with overall radiation toxicity. Int J Radiat Oncol Biol Phys 2012: 84: 1031–1036.
51. Knappskog S, Chrisanthar R, Lokkevik E et al. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res 2012: 14: R47.
52. Kweekel DM, Antonini NF, Nortier JW, Punt CJ, Gelderblom H, Guchelaar HJ. Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. Br J Cancer 2009: 101: 357–362.
53. Mercer JR, Cheng KK, Figg N et al. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res 2010: 107: 1021–1031.
54. Wu D, Yang H, Xiang W et al. Heterozygous mutation of ataxia-telangiectasia mutated gene aggravates hypercholesterolemia in apoE-deficient mice. J Lipid Res 2005: 46: 1380–1387.
55. Smirnov DA, Cheung VG. ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs. Am J Hum Genet 2008: 83: 243–253.
56. Foster CR, Daniel LL, Daniels CR, Dalal S, Singh M, Singh K. Deficiency of ataxia telangiectasia mutated kinase modulates cardiac remodeling following myocardial infarction: involvement in fibrosis and apoptosis. PLoS One 2013: 8: e83513.
57. Schneider JG, Finck BN, Ren J et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006: 4: 377–389.
58. Eilam R, Peter Y, Groner Y, Segal M. Late degeneration of nigro-striatal neurons in ATM−/− mice. Neuroscience 2003: 121: 83–98.
59. Kruman II, Wersto RP, Cardozo-Pelaez F et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 2004: 41: 549–561.
60. Macleod MR, Ramage L, McGregor A, Seckl JR. Reduced NMDA-induced apoptosis in neurons lacking ataxia telangiectasia mutated protein. Neuroreport 2003: 14: 215–217.
61. Camins A, Pizarro JG, Alvira D et al. Activation of ataxia telangiectasia muted under experimental models and human Parkinson's disease. Cell Mol Life Sci 2010: 67: 3865–3882.
62. Yang Y, Herrup K. Loss of neuronal cell cycle control in ataxia-telangiectasia: a unified disease mechanism. J Neurosci 2005: 25: 2522–2529.
63. Volkow ND, Tomasi D, Wang GJ, Studentsova Y, Margus B, Crawford TO. Brain glucose metabolism in adults with ataxia-telangiectasia and their asymptomatic relatives. Brain 2014: 137: 1753–1761.
64. Barlow C, Hirotsune S, Paylor R et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996: 86: 159–171.
65. Daniel JA, Pellegrini M, Lee BS et al. Loss of ATM kinase activity leads to embryonic lethality in mice. J Cell Biol 2012: 198: 295–304.
66. Boder E. Ataxia-telangiectasia: some historic, clinical and pathologic observations. Birth Defects Orig Artic Ser 1975: 11: 255–270.
67. American Society of Clinical Oncology (ASCO): Ataxia-Telangiectasia 2014, Retrieved from http://www.cancer.net/cancer-types/ataxia-telangiectasia
68. USA National Cancer Institute (NCI): Ataxia Telangiectasia 2006, Retrieved from http://www.cancer.gov/about-cancer/causes-prevention/genetics/ataxia-fact-sheet#q12